Suppr超能文献

估算泰国人对质量调整生命年的支付意愿:健康改善的背景是否重要?

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

作者信息

Thavorncharoensap Montarat, Teerawattananon Yot, Natanant Sirin, Kulpeng Wantanee, Yothasamut Jomkwan, Werayingyong Pitsaphun

机构信息

Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand ; Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand.

出版信息

Clinicoecon Outcomes Res. 2013;5:29-36. doi: 10.2147/CEOR.S38062. Epub 2013 Jan 9.

Abstract

BACKGROUND

This study aims to elicit the value of the willingness to pay (WTP) for a quality-adjusted life year (QALY) and to examine the factors associated with the WTP for a QALY (WTP/QALY) value under the Thai health care setting.

METHODS

A community-based survey was conducted among 1191 randomly selected respondents. Each respondent was interviewed face-to-face to elicit his/her health state preference in each of three pairs of health conditions: (1) unilateral and bilateral blindness, (2) paraplegia and quadriplegia, and (3) mild and moderate allergies. A visual analog scale (VAS) and time trade off (TTO) were used as the eliciting methods. Subsequently, the respondents were asked about their WTP for the treatment and prevention of each pair of health conditions by using a bidding-game technique.

RESULTS

With regards to treatment, the mean WTP for a QALY value (WTP/QALY(treatment)) estimated by the TTO method ranged from 59,000 to 285,000 baht (16.49 baht = US$1 purchasing power parity [PPP]). In contrast, the mean WTP for a QALY value in terms of prevention (WTP/QALY(prevention)) was significantly lower, ranging from 26,000 to 137,000 baht. Gender, household income, and hypothetical scenarios were also significant factors associated with the WTP/QALY values.

CONCLUSION

The WTP/QALY values elicited in this study were approximately 0.4 to 2 times Thailand's 2008 GDP per capita. These values were in line with previous studies conducted in several different settings. This study's findings clearly support the opinion that a single ceiling threshold should not be used for the resource allocation of all types of interventions.

摘要

背景

本研究旨在得出质量调整生命年(QALY)的支付意愿(WTP)值,并考察泰国医疗保健环境下与QALY支付意愿(WTP/QALY)值相关的因素。

方法

对1191名随机抽取的受访者进行了一项基于社区的调查。每位受访者都接受了面对面访谈,以了解其在三对健康状况中的每一对中的健康状态偏好:(1)单眼失明和双眼失明,(2)截瘫和四肢瘫,以及(3)轻度和中度过敏。采用视觉模拟量表(VAS)和时间权衡法(TTO)作为获取偏好的方法。随后,通过投标博弈技术询问受访者对每对健康状况的治疗和预防的支付意愿。

结果

在治疗方面,通过TTO方法估计的QALY值的平均支付意愿(WTP/QALY(治疗))范围为59,000至285,000泰铢(16.49泰铢 = 1美元购买力平价[PPP])。相比之下,预防方面的QALY值的平均支付意愿(WTP/QALY(预防))显著较低,范围为26,000至137,000泰铢。性别、家庭收入和假设情景也是与WTP/QALY值相关的重要因素。

结论

本研究得出的WTP/QALY值约为泰国2008年人均国内生产总值的0.4至2倍。这些值与先前在几个不同环境中进行的研究一致。本研究的结果明确支持以下观点,即不应将单一的上限阈值用于所有类型干预措施的资源分配。

相似文献

1
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Clinicoecon Outcomes Res. 2013;5:29-36. doi: 10.2147/CEOR.S38062. Epub 2013 Jan 9.
3
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
4
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
Cost Eff Resour Alloc. 2020 Oct 23;18:47. doi: 10.1186/s12962-020-00241-9. eCollection 2020.
6
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.
Clinicoecon Outcomes Res. 2014 Oct 23;6:473-81. doi: 10.2147/CEOR.S67375. eCollection 2014.
7
Willingness to pay for a quality-adjusted life-year: the individual perspective.
Value Health. 2010 Dec;13(8):1046-55. doi: 10.1111/j.1524-4733.2010.00781.x. Epub 2010 Sep 3.
8
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
10
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
Cost Eff Resour Alloc. 2023 Jun 5;21(1):37. doi: 10.1186/s12962-023-00442-y.

引用本文的文献

2
Cost-utility analysis of botulinum toxin type A versus oral drug treatment in patients with severe blepharospasm in Thailand.
PLoS One. 2025 Apr 21;20(4):e0319926. doi: 10.1371/journal.pone.0319926. eCollection 2025.
6
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.
Appl Health Econ Health Policy. 2024 Nov;22(6):797-804. doi: 10.1007/s40258-024-00900-5. Epub 2024 Jul 12.
10
Health-related quality of life and willingness to pay measurement among patients on warfarin in Thailand.
J Pharm Policy Pract. 2023 Oct 30;16(1):130. doi: 10.1186/s40545-023-00632-2.

本文引用的文献

2
The social value of a QALY: raising the bar or barring the raise?
BMC Health Serv Res. 2011 Jan 11;11:8. doi: 10.1186/1472-6963-11-8.
3
Willingness to pay for a quality-adjusted life-year: the individual perspective.
Value Health. 2010 Dec;13(8):1046-55. doi: 10.1111/j.1524-4733.2010.00781.x. Epub 2010 Sep 3.
4
Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
Value Health. 2009 Nov-Dec;12 Suppl 3:S4-11. doi: 10.1111/j.1524-4733.2009.00620.x.
5
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
6
Willingness to pay for a QALY: past, present and future.
Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):575-82. doi: 10.1586/14737167.8.6.575.
7
Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.
Health Qual Life Outcomes. 2010 Mar 12;8:28. doi: 10.1186/1477-7525-8-28.
9
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?
Expert Rev Pharmacoecon Outcomes Res. 2004 Jun;4(3):247-50. doi: 10.1586/14737167.4.3.247.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验